title: Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantation: use of high doses of the new monoclonal antibody BMA 031.
authors.affiliation: Division of Transplant Surgery, Klinikum Grosshadern, University of Munich, FRG.
authors.forename: U
authors.initials: U
authors.lastname: Dendorfer
authors.forename: G
authors.initials: G
authors.lastname: Hillebrand
authors.forename: C
authors.initials: C
authors.lastname: Kasper
authors.forename: S
authors.initials: S
authors.lastname: Smely
authors.forename: M
authors.initials: M
authors.lastname: Weschka
authors.forename: C
authors.initials: C
authors.lastname: Hammer
authors.forename: J
authors.initials: J
authors.lastname: Racenberg
authors.forename: H J
authors.initials: HJ
authors.lastname: Gurland
authors.forename: W
authors.initials: W
authors.lastname: Land
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007432:Intraoperative Period; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D001379:Azathioprine; D008775:Methylprednisolone